Literature DB >> 19745746

Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

Stephen Waldek1, Manesh R Patel, Maryam Banikazemi, Roberta Lemay, Philip Lee.   

Abstract

PURPOSE: To evaluate life expectancy and cause of death among patients with Fabry disease, an X-linked lysosomal storage disorder.
METHODS: Data from 2848 patients in the Fabry Registry were summarized using descriptive statistics. Life expectancy at birth was compared with that of the United States general population.
RESULTS: As of August 2008, 75 of 1422 males and 12 of 1426 females in the Fabry Registry were reported to have died. The 87 deceased patients were diagnosed at a much older age than other patients in the Fabry Registry: median age at diagnosis was 40 vs. 24 years in males and 55 vs. 33 years in females. The life expectancy of males with Fabry disease was 58.2 years, compared with 74.7 years in the general population of the United States. The life expectancy of females with Fabry disease was 75.4 years, compared with 80.0 years in the United States general population. The most common cause of death among both genders was cardiovascular disease. Most (57%) patients who died of cardiovascular disease had previously received renal replacement therapy.
CONCLUSIONS: Most deceased Fabry Registry patients exhibited serious cardiac and renal dysfunction. Late diagnosis may have contributed to the early deaths of these patients.

Entities:  

Mesh:

Year:  2009        PMID: 19745746     DOI: 10.1097/GIM.0b013e3181bb05bb

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  94 in total

Review 1.  Fabry disease, enzyme replacement therapy and the significance of antibody responses.

Authors:  Patrick B Deegan
Journal:  J Inherit Metab Dis       Date:  2011-10-25       Impact factor: 4.982

Review 2.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

Authors:  Praveen G Ranganath; Albree Tower-Rader
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

3.  Gastrointestinal phenotype of fabry disease in a patient with pseudoobstruction syndrome.

Authors:  Piotr Buda; Anna Wieteska-Klimczak; Janusz Ksiazyk; Piotr Gietka; Anna Smorczewska-Kiljan; Maciej Pronicki; Barbara Czartoryska; Anna Tylki-Szymanska
Journal:  JIMD Rep       Date:  2011-11-04

4.  Fabry disease in latin america: data from the fabry registry.

Authors:  J Villalobos; J M Politei; A M Martins; G Cabrera; H Amartino; R Lemay; S Ospina; S Suarez Ordoñez; C Varas
Journal:  JIMD Rep       Date:  2012-07-06

Review 5.  Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.

Authors:  Malte Lenders; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2018-08-09       Impact factor: 10.121

6.  Use of lissamine rhodamine ceramide trihexoside as a functional assay for alpha-galactosidase A in intact cells.

Authors:  Christine R Kaneski; Raphael Schiffmann; Roscoe O Brady; Gary J Murray
Journal:  J Lipid Res       Date:  2010-06-06       Impact factor: 5.922

Review 7.  The Genetic Challenges and Opportunities in Advanced Heart Failure.

Authors:  Fady Hannah-Shmouni; Sara B Seidelmann; Sandra Sirrs; Arya Mani; Daniel Jacoby
Journal:  Can J Cardiol       Date:  2015-08-21       Impact factor: 5.223

8.  Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease.

Authors:  Markus Niemann; Tanja Hartmann; Mehdi Namdar; Frank Breunig; Meinrad Beer; Wolfram Machann; Sebastian Herrmann; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

9.  Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Authors:  John Marshall; Karen M Ashe; Dinesh Bangari; KerryAnne McEachern; Wei-Lien Chuang; Joshua Pacheco; Diane P Copeland; Robert J Desnick; James A Shayman; Ronald K Scheule; Seng H Cheng
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

Review 10.  Fabry disease: raising awareness of the disease among physicians.

Authors:  Francesca Carubbi; Lisa Bonilauri
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.